Summit Therapeutics (SMMT) EBITDA (2019 - 2026)
Summit Therapeutics (SMMT) reported EBITDA of -$189.5 million for Q1 2026, down 199.91% on a YoY basis from $189.7 million in Q1 2025, and up 13.46% quarter-over-quarter from -$219.0 million in Q4 2025.
Summit Therapeutics (SMMT) EBITDA (2019 - 2026) Analysis & Trends
Summit Therapeutics has reported EBITDA for 8 years, with the latest figure at -$189.5 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 199.91% year-over-year to -$189.5 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (down 400.96% YoY), and the FY2025 full-year result was -$1.1 billion, down 388.28% from the prior year.
- EBITDA for Q1 2026 stood at -$189.5 million, up from -$219.0 million in the prior quarter.
- The five-year high for EBITDA was -$15.8 million in Q2 2023, with the low at -$565.9 million in Q2 2025.
- Historically, EBITDA has averaged -$128.5 million across 5 years, with a median of -$56.1 million in 2024.
- Annual changes were most pronounced in 2023 — EBITDA plunged 2240.02% — and 2024, when it soared 91.98%.
- Summit Therapeutics' EBITDA stood at -$17.9 million in 2022, then slumped by 104.93% to -$36.7 million in 2023, then tumbled by 66.74% to -$61.2 million in 2024, then slumped by 257.97% to -$219.0 million in 2025, then grew by 13.46% to -$189.5 million in 2026.
- The last three EBITDA figures came in at -$189.5 million (Q1 2026), -$219.0 million (Q4 2025), and -$231.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -65.83 Mn |
| 10 | Summit Therapeutics | 11.10 Bn | 10.99 Bn | - | -189.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -189.52 Mn |
| Dec 31, 2025 | -219.00 Mn |
| Sep 30, 2025 | -231.75 Mn |
| Jun 30, 2025 | -565.90 Mn |
| Mar 31, 2025 | -63.19 Mn |
| Dec 31, 2024 | -61.18 Mn |
| Sep 30, 2024 | -56.06 Mn |
| Jun 30, 2024 | -60.34 Mn |
| Mar 31, 2024 | -43.47 Mn |
| Dec 31, 2023 | -36.69 Mn |
| Sep 30, 2023 | -21.15 Mn |
| Jun 30, 2023 | -15.76 Mn |
| Mar 31, 2023 | -541.88 Mn |
| Dec 31, 2022 | -17.91 Mn |
| Sep 30, 2022 | -21.43 Mn |
| Jun 30, 2022 | -15.98 Mn |
| Mar 31, 2022 | -23.16 Mn |
| Dec 31, 2021 | -25.85 Mn |
| Sep 30, 2021 | -20.46 Mn |
| Jun 30, 2021 | -23.88 Mn |